leadf
logo-loader
viewCytoDyn Inc.

CytoDyn selected to make oral presentation at the “Special isirv-AVG Virtual Conference on Therapeutics for COVID-19”

The company has been chosen to talk about its completed Phase 2 study of leronlimab for mild-to-moderate coronavirus (COVID-19) patients

CytoDyn Inc. - CytoDyn selected to make oral presentation at the “Special isirv-AVG Virtual Conference on Therapeutics for COVID-19”
Enrollment continues in CytoDyn’s Phase 3 randomized clinical trial for severe-to-critically ill COVID-19 patients in several hospitals in the US and an interim analysis on the first 195 patients will be shared by mid-October

CytoDyn Inc (OTCQB:CYDY), which is developing its flagship drug leronlimab (PRO 140) to battle multiple diseases, said Wednesday that its Phase 2 study of leronlimab for mild-to-moderate coronavirus (COVID-19) patients has been selected for an oral presentation at the upcoming "Special isirv-Antiviral Conference on Therapeutics for COVID-19.”

The three-day conference starting on October 6 is sponsored by the UK-based International Society for Influenza and other Respiratory Virus Diseases.

“The acceptance of this oral abstract by this highly regarded scientific organization is very rewarding for all of the medical professionals who provided care and treatment to the COVID-19 patients during our Phase 2 trial,” said CytoDyn CEO Nader Pourhassan.

“We also view this acceptance as a validation of leronlimab as a potential therapeutic for this disease and we look forward to the upcoming interim analysis from our Phase 3 trial for severe-to-critical COVID-19 patients.”

READ: CytoDyn to meet with UK regulators to discuss Fast-Track approval for leronlimab, schedules sitdown with FDA

Vancouver, Washington-based CytoDyn completed its Phase 2 trial to evaluate the effectiveness and safety of leronlimab in patients with mild-to-moderate symptoms caused by COVID-19 infection in July this year.

Patients were randomized to receive weekly doses of 700 mg leronlimab, or placebo. Leronlimab and placebo were administered through injections. The patients receiving leronlimab experienced 64% fewer serious adverse events (SAEs) during the trial than patients receiving placebo

The Phase 2 clinical trial for mild-to-moderate patients in the US produced statistically significant results for NEWS2. Enrollment continues in CytoDyn’s Phase 3 randomized clinical trial for severe-to-critically ill COVID-19 patients in several hospitals in the US. An interim analysis on the first 195 patients will be shared by mid-October.

Details of the presentation are as follows:

  • Abstract Title: A Phase 2 Study of Leronlimab for mild-to-moderate coronavirus disease (COVID-19).
  • Abstract Confirmation Number: AAVGV0010
  • Presenter: Harish Seethamraju, medical director, Advanced Lung Failure and Lung Transplant, Montefiore Medical Center, Bronx, New York.
  • Presentation Date: October 6-8, 2020
  • Time: 12.00-4.00pm GMT and will be available on demand.
  • Additional details can be found on the conference web site here

The FDA has granted Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.

Contact the author Uttara Choudhury at [email protected]com

Follow her on Twitter: @UttaraProactive

Quick facts: CytoDyn Inc.

Price: 2.39 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.38 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn provide update on their path to approval for treatment of COVID-19

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to provide an update on how and when they expect to have approval for Leronlimab for Covid treatment.  Pourhassan also told Proactive about what the recent decision by the FDA to approve Remdesivir as a...

6 days, 1 hour ago

2 min read